Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tonix Pharm Holdings 26 MAIN STREET SUITE 101 CHATHAM NJ 07928 USA

www.tonixpharma.com Employees: 76 P: 862-799-9155 F: 212-923-5700

Description:

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.

Key Statistics

Overview:

Market Capitalization, $K 17,994
Enterprise Value, $K 1,954
Shares Outstanding, K 137,256
Annual Sales, $ 7,770 K
Annual Net Income, $ -116,660 K
Last Quarter Sales, $ 2,210 K
Last Quarter Net Income, $ -78,780 K
EBIT, $ -154,150 K
EBITDA, $ -149,860 K
60-Month Beta 2.06
% of Insider Shareholders 0.04%
% of Institutional Shareholders 82.26%
Float, K 137,201
% Float 99.96%
Short Volume Ratio 0.70

Growth:

1-Year Return -99.12%
3-Year Return -100.00%
5-Year Return -100.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.23 on 11/12/24
Next Earnings Date 11/14/24
Earnings Per Share ttm -110.98
EPS Growth vs. Prev Qtr 98.81%
EPS Growth vs. Prev Year 99.61%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-32 on 06/10/24

TNXP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -163.95%
Return-on-Assets % -118.88%
Profit Margin % -1,501.42%
Debt/Equity 0.20
Price/Sales 2.47
Price/Cash Flow N/A
Price/Book 0.26
Book Value/Share 2.41
Interest Coverage -2.36
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar